# OnCo record paper-emerald-elacestrant-jco-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-emerald-elacestrant-jco-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-emerald-elacestrant-jco-2022" ;
  schema:name "EMERALD: elacestrant versus standard endocrine therapy after a CDK4/6 inhibitor"@en ;
  schema:description "The oral oestrogen receptor degrader elacestrant delayed progression compared with standard hormone therapy in advanced breast cancer that had progressed on a CDK4/6 inhibitor, with the clearest benefit in tumours carrying an ESR1 mutation."@en ;
  schema:url <https://onco.cc/key-papers/paper-emerald-elacestrant-jco-2022/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.22.00338>, <https://pubmed.ncbi.nlm.nih.gov/35584336/> ;
  schema:sameAs <https://doi.org/10.1200/JCO.22.00338> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Bidard FC, Kaklamani VG, Neven P, et al." ;
  onco:cancers <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/> ;
  onco:drugs <https://onco.cc/drugs/elacestrant/> ;
  onco:trials <https://onco.cc/trials/emerald/> ;
  onco:journals <https://onco.cc/journals/jco/> .